Payer and Implementation Challenges with Advanced Therapy Medicinal Products (ATMPs) John SpoorsAlec MinersSheena Vithlani Current Opinion 23 November 2020 Pages: 1 - 5
Emerging Targeted Therapies for Neuromyelitis Optica Spectrum Disorders Cristina Valencia-SanchezDean M. Wingerchuk Leading Article 10 December 2020 Pages: 7 - 17
Current and Emerging Targeted Therapies for Acute Graft-Versus-Host Disease Stelios KasikisAaron EtraJohn E. Levine Review Article 17 November 2020 Pages: 19 - 33
Systematic Review and Principal Components Analysis of the Immunogenicity of Adalimumab Rodrigo BorregaCarlos AraújoJoao Goncalves Systematic Review 10 December 2020 Pages: 35 - 45
Administration of CD4+CD25highCD127−FoxP3+ Regulatory T Cells for Relapsing-Remitting Multiple Sclerosis: A Phase 1 Study Kamil ChwojnickiDorota Iwaszkiewicz-GrześPiotr Trzonkowski Original Research Article 05 January 2021 Pages: 47 - 60
Effect of Treatment with the PD-1/PD-L1 Inhibitors on Key Health Outcomes of Cancer Patients Kyung-In JoungJong Hwa SongDong Churl Suh Original Research Article 17 December 2020 Pages: 61 - 73
A Look at the History of Biosimilar Adoption: Characteristics of Early and Late Adopters of Infliximab and Etanercept Biosimilars in Subregions of England, Scotland and Wales - A Mixed Methods Study Evelien MoorkensArnold G. VultoIsabelle Huys Original Research Article Open access 11 December 2020 Pages: 75 - 87
Budget Impact Analysis of the Introduction of Rituximab and Trastuzumab Intravenous Biosimilars to EU-5 Markets Minyoung JangSteven SimoensTaeksang Kwon Original Research Article Open access 24 December 2020 Pages: 89 - 101
Biosimilar Perceptions Among Healthcare Professionals and Commercial Medical Benefit Policy Analysis in the United States Kyle HerndonJason BraithwaiteKathleen Bourget Original Research Article 05 January 2021 Pages: 103 - 112
